New Publication Highlights Preclinical Research Showing Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo® (cemiplimab)

Wednesday, June 24, 2020 1 min read

Key Takeaway: New Publication Highlights Preclinical Research Showing Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo® (cemiplimab)

Full Press Release Details

New Publication Highlights Preclinical Research Showing Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo® (cemiplimab).

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Full Press Release Details